Coronavirus disease 2019 (COVID-19), with a high prevalence rate, has rapidly infected millions of people around the world. Since viral infections can disrupt the coagulation and homeostasis cascades, various inflammatory and coagulation problems occur due to COVID-19 infection, similar to coronavirus epidemics in 2003 and 2004. According to multiple previous studies, in the present research, we reviewed the most commonly reported problems of COVID-19 patients, such as venous thromboembolism, pulmonary embolism, disseminated intravascular coagulation, etc. and investigated the causes in these patients. Coagulation and inflammatory markers, such as platelets and fibrinogen, C-reactive protein, lactate dehydrogenase, d-dimer, prothrombin time, etc., were also discussed, and the treatment options were briefly reviewed. In addition to coagulation treatments, regular examination of coagulation parameters and thrombotic complications can be helpful in the timely treatment of patients. Therefore, it is helpful to review the coagulation problems in COVID-19 patients. Although all mentioned problems and markers are important in COVID-19, some of them are more valuable in terms of diagnosis and prognosis.

For comparison of the infection index in treatments, the greenhouse experiment was performed with a split plot arranged in a randomized complete block design with four replications. Result of greenhouse experiments on different types of T. flavus treatments indicated that there was no significant difference among them. However, among five T. flavus isolates, the most effective one was Tf-To-V-24 and Tf-To-U-36. In the experiment on the interaction between different T. flavus treatments and T. flavus isolates, a minimum infection index was observed when both soil and seed were treated with Tf-To-V-31. The overall results of this study show that it may be possible to manage tomato Verticillium wilt disease effectively by T. flavus.

Novel Coronavirus, also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in December 2019 in China and spread rapidly all around the world infecting many people. To date, no specific vaccines and drugs have been developed for this disease. Also, due to the COVID-19 pandemic and high prevalence of the infected patients, the drugs and the therapies of other past viral epidemics have been used for this disease. Many studies have been performed on the specific treatments to find whether or not they are effective on COVID-19 patients. In this review, we collected information about the most widely used drugs to treat COVID-19 (coronavirus disease 2019) belonging to groups of antivirals, antibiotics, immune modulators, and anticoagulants. Some of these compounds and drugs were used directly by inpatients, so researchers have examined others in laboratory conditions. This study considered the pros and cons of using these treatments separately and together and compared their results. By studying this review, we hope to provide useful information for researchers.

No abstract

Colistin relates to the polymyxin group of antibiotics. This antibiotic is still used to destroy gram-negative bacteria as a last resort. However, resistance to this antibiotic has been reported and is appearing day by day. Not much information is available on the exact mechanisms of resistance to this antibiotic. Also, not enough information about pharmacokinetics and pharmacodynamics is available, so the optimal dose should be determined to use these antibiotics to prevent the toxic effects of this antibiotic. In current study, additionally to their pharmacokinetics and pharmacodynamics, we have presented current knowledge about the genes and two-component systems that may cause such resistance to polymyxin and colistin.